Yangling Li1,2, Dongmei Zhou1, Shuang Xu1, Mingjun Rao3, Zuoyan Zhang4, Linwen Wu4, Chong Zhang4, Nengming Lin1,2,3. 1. Department of Clinical Pharmacology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou 310006, China. 2. Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China. 3. Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China. 4. School of Medicine, Zhejiang University City College, Hangzhou 310015, China.
In the published paper[1], errors appeared in on page 391. In , an incorrect gel image was shown for Bcl-xL in NCI-H1299 cells. has been updated to correct the mistake above. The errors do not affect the conclusions of this article. We apologize for the errors and for any confusion that they may have caused.(C) NSCLC cells were treated with harmine at the indicated concentrations for 24 h, and the expression of the indicated proteins were detected by Western blot. (D) NSCLC cells were treated with 20 µM harmine for 1, 3, 6, 9, and 12 h, and the expression of the indicated proteins was detected by Western blot.